查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1923001

按产品类型、技术、检体类型、应用和最终用户分類的即时检测或快速诊断市场—2026-2032年全球预测

Point-Of-Care Or Rapid Diagnostics Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，即时检测或快速诊断市场价值为 356.1 亿美元，预计到 2026 年将成长至 386.2 亿美元，年复合成长率为 9.56%，到 ​​2032 年将达到 675.2 亿美元。

关键市场统计数据
基准年 2025 356.1亿美元
预计年份：2026年 386.2亿美元
预测年份 2032 675.2亿美元
复合年增长率 (%) 9.56%

快速诊断在现代医疗保健服务中不断演变的角色，以及它如何影响临床和商业相关人员的策略重点。

在不断变化的患者期​​望、技术小型化以及及时做出临床决策的需求推动下，照护现场快速诊断已从边缘临床工具转变为现代诊疗路径的核心要素。本文回顾了当前情势，重点阐述了诊断速度、可及性和准确性如何重塑门诊、住院和家庭监测的工作流程。文章还概述了医疗设备製造商、诊断实验室、支付方和医疗系统在临床性能、易用性和成本控制方面所面临的策略挑战。

小型化检测平台、整合式医疗服务模式和实证商业化的整合正在重塑即时诊断。

照护现场诊断领域正经历技术、医疗服务模式和相关人员期望等方面的变革。分子方法、微流体整合和电化学感测技术的进步，使得以往需要在中心检查室进行的检测能够在床边或家中完成，且性能与中心实验室相当。这些技术进步催生了新的医疗服务模式，包括行动检测单元、扩展的家庭监测和整合式数位健康平台，从而重塑了诊断资讯融入临床决策的路径。因此，临床团队正在重新设计工作流程，将快速检测结果纳入同一诊疗方案，从而加快治疗启动速度并改善患者体验。

美国近期关税政策如何促使相关人员重组供应链、调整筹资策略、定价和合规措施。

美国2025年实施的新关税制度和贸易政策引发了一系列贸易摩擦，对整个供应链的运作和策略都产生了即时影响。製造商和经销商正在透过重新评估筹资策略、增加关键零件库存以及实现供应商多元化来应对这些挑战，以降低关税波动带来的风险。因此，采购团队优先考虑对供应商进行实质审查，并在条件允许的情况下寻找近岸外包的机会；产品开发团队则在评估如何透过设计变更来减少对高关税零件的依赖，同时又不影响产品效能。

策略性细分互动涵盖产品类型、最终用户、应用、技术、分销管道和检体类型，指导产品和商业化优先排序。

深入了解市场区隔对于协调产品设计、证据产生和市场推广策略至关重要。从产品类型来看，市场涵盖凝血、内分泌、血液学、免疫化学、侧向层析免疫检测、分子诊断和尿液分析。凝血平台进一步细分为PT/INR检测仪和血栓弹力图仪；内分泌解决方案细分为血糖仪和胰岛素帮浦；血液学细分为血红蛋白仪和白血球计数仪；免疫化学细分为化学冷光免疫免疫检测、酵素免疫分析法和萤光免疫分析；侧向层析检测细分为抗体、抗原和尿液检查用于分子分析仪等温次世代定序等温序增序分析。了解这些产品之间的差异有助于明确每种环境下的效能、监管和易用性预期。

区域监管差异、采购趋势和数位基础设施正在推动美洲、欧洲、中东和非洲以及亚太地区采取差异化的策略。

区域趋势差异显着，应体现在打入市场策略和监管计画的製定。在美洲，持续重视整合式医疗网路、基于价值的报销试验计画以及医疗服务提供者的整合，正在塑造对能够带来可衡量疗效和营运效率的医疗设备的需求。同时，欧洲、中东和非洲（EMEA）的监管和报销环境各不相同，各国的卫生技术评估流程和采购惯例要求制定量身定制的打入市场策略。在一些国家，公开竞标和与医院集团的谈判是产品推广的关键。在亚太地区，市场成熟度因区域而异，一些市场正在迅速采用照护现场分子检测和家庭监测解决方案，而另一些市场则优先考虑扩充性、低成本的侧向层析和电化学平台，以扩大检测范围。

竞争格局结合了现有企业的规模、Start-Ups的敏捷性和策略联盟，透过证据、连结性和使用者体验来推动照护现场诊断领域的差异化。

照护现场领域的竞争格局由成熟的诊断设备製造商、快速发展的临床Start-Ups和专业平台提供者组成。现有企业利用其丰富的产品系列、成熟的分销网络和与医院的现有关係来巩固市场地位，而灵活的新参与企业则专注于以用户为中心的设计、快速迭代以及针对特定应用场景和终端用户群的循证项目。随着连结性和数据分析能力成为贯穿整个医疗流程、释放价值的差异化因素，诊断开发人员和数位医疗供应商之间的合作正在加速发展。

透过基于实证的产品和通路策略，采取切实有效的领导行动，确保临床应用、供应保障和商业性扩充性。

产业领导者应采取积极进取、多管齐下的策略，整合产品开发、证据收集和商业性执行。优先考虑以最终用户为中心的解决方案设计，在诊所、医院、医生办公室、行动检测单元和居家照护环境中进行迭代式可用性研究，以减轻培训负担并优化工作流程整合。同时，投资于以循环系统、糖尿病监测、感染疾病学和妊娠检测等应用领域为重点的实用性临床试验和真实世界证据项目，以在对支付方和医疗服务提供方至关重要的场景中证明临床效用和经济价值。

结合关键相关人员访谈、技术基准测试、文献综述以及产业趋势和政策分析等多源研究途径，确保得出切实可行的见解。

本分析的调查方法结合了多方面视角，旨在提供平衡且实用的观点。主要研究包括对临床医生、采购负责人和行业高管进行结构化访谈，以了解医院、诊所、行动检测服务机构、医生办公室和居家照护课程中的本地可用性见解和采购重点。次要研究则透过评估同侪审查文献、监管指导文件和公共临床试验註册库，检验了技术趋势和临床证据的发展轨迹。

为寻求将快速诊断纳入护理路径和商业生态系统的产品开发人员和医疗保健领导者总结策略要务

总之，照护现场和快速诊断正处于策略转折点，技术能力、医疗服务转型和商业性创新在此交汇融合，重新定义了诊断决策的製定地点和方式。在这种环境下取得成功，需要的不仅仅是卓越的分析能力；它还需要整合策略，该战略需兼顾临床效用、用户体验、供应链韧性以及能够引起支付方和医疗服务提供方共鸣的证据。那些能够将产品开发与实际应用案例结合、积极管理地缘政治和关税相关风险并部署灵活的分销和商业化模式的利益相关人员，将更有利于抓住新的机会。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的即时诊断或快速诊断市场

  • 凝血
    • PT INR测量仪器
    • 血栓弹力图装置
  • 内分泌学
    • 血糖仪
    • 胰岛素帮浦
  • 血液学
    • 血红素测量装置
    • 白血球计数器
  • 免疫化学
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 萤光免疫分析
  • 侧向流动免疫检测
    • 抗体检测
    • 抗原检测
    • 多重测试
  • 分子诊断
    • 等温扩增
    • 次世代定序
    • PCR
  • 尿液检查
    • 分析仪器系统
    • 测试条

9. 按技术分類的即时诊断或快速诊断市场

  • 电化学检测
  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
    • 萤光免疫分析
    • 侧向流动免疫检测
  • 微流体平台
  • 分子诊断
    • 等温扩增
    • 次世代定序
    • PCR
  • 光学检测

10. 按检体类型分類的即时检测或快速诊断市场

  • 血
  • 吐气
  • 唾液
  • 尿

11. 按应用分類的即时诊断或快速诊断市场

  • 心臟病学
  • 糖尿病监测
  • 感染疾病
  • 肿瘤学
  • 妊娠测试

12. 按最终用户分類的即时诊断或快速诊断市场

  • 诊所
  • 居家照护
  • 医院
  • 移动侦测
  • 医生诊所

13. 按地区分類的即时诊断或快速诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按群体分類的即时诊断或快速诊断市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国即时诊断或快速诊断市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国即时检测或快速诊断市场

17. 中国即时诊断或快速诊断市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Acon Laboratories, Inc.
  • Becton Dickinson and Company
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • Hologic, Inc.
  • Jianchun Biological Technology Co., Ltd.
  • Meridian Bioscience, Inc.
  • Nova Biomedical Corporation
  • OraSure Technologies, Inc.
  • Polymer Technology Systems, Inc.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Response Biomedical Corp.
  • Samsung Electronics Co., Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Trinity Biotech plc
  • Veredus Laboratories Pte Ltd
Product Code: MRR-867BED9A9EB7

The Point-Of-Care Or Rapid Diagnostics Market was valued at USD 35.61 billion in 2025 and is projected to grow to USD 38.62 billion in 2026, with a CAGR of 9.56%, reaching USD 67.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 35.61 billion
Estimated Year [2026] USD 38.62 billion
Forecast Year [2032] USD 67.52 billion
CAGR (%) 9.56%

Framing the evolving role of rapid diagnostics in contemporary healthcare delivery and strategic priorities for clinical and commercial stakeholders

Point-of-care and rapid diagnostics have moved from peripheral clinical tools to central elements of modern care pathways, driven by evolving patient expectations, technological miniaturization, and the imperative for timely clinical decision-making. This introduction frames the current landscape by highlighting how diagnostic speed, accessibility, and accuracy are reshaping workflows across ambulatory care, inpatient settings, and home-based monitoring. It outlines the strategic implications for device manufacturers, diagnostic laboratories, payers, and health systems who must reconcile clinical performance with usability and cost constraints.

The interplay between regulatory clarity and accelerated approval pathways has created an environment where innovation can translate to practice rapidly, provided that validation and real-world evidence are prioritized. In addition, shifting reimbursement models that emphasize value over volume are incentivizing solutions that demonstrably reduce downstream costs through early detection and treatment optimization. Taken together, these forces underscore an urgent need for clear product differentiation and robust evidence generation strategies as developers transition prototypes into scalable offerings. This introduction sets expectations for the subsequent sections by emphasizing practical adoption barriers, competitive levers, and strategic priorities that stakeholders must address to succeed in a dynamic point-of-care market.

Convergence of compact assay platforms, integrated care delivery models, and evidence-driven commercialization reshaping point-of-care diagnostics

The landscape for point-of-care diagnostics is undergoing transformative shifts that span technology, care delivery models, and stakeholder expectations. Advances in molecular methods, microfluidic integration, and electrochemical sensing are enabling assays that once required centralized laboratories to be performed at bedside or in-home with comparable performance characteristics. These technological advances are being accompanied by new care delivery models that incorporate mobile testing units, expanded home monitoring, and integrated digital health platforms, each reshaping the pathways by which diagnostic information flows into clinical decision-making. Consequently, clinical teams are reconfiguring workflows to incorporate rapid test results into same-encounter care plans, accelerating treatment initiation and improving patient experience.

Parallel to technical progress, commercial dynamics are evolving as distribution channels diversify and digital procurement gains traction. Evolving payer expectations and the need for demonstrable clinical utility are driving manufacturers to invest in outcomes studies and health economics evidence that can justify placement across hospitals, clinics, and home care. Furthermore, interoperability and data integration are becoming table stakes, as stakeholders demand secure and standardized methods to aggregate real-world diagnostic data for population health management and quality measurement. These combined shifts are recalibrating competitive advantage from purely analytical performance to include user experience, connectivity, and proven clinical impact.

How recent United States tariff developments have prompted supply chain realignment, procurement strategy adjustments, and pricing and compliance adaptations across stakeholders

The introduction of new tariff regimes and trade policies in the United States in 2025 introduced a set of trade-related frictions with immediate operational and strategic effects across supply chains. Manufacturers and distributors have responded by reassessing sourcing strategies, increasing inventories of critical components, and diversifying supplier bases to mitigate exposure to tariff volatility. As a result, procurement teams have prioritized supplier due diligence and nearshoring opportunities where feasible, while product development groups are evaluating design changes that reduce dependency on high-tariff components without compromising performance.

These policy-driven adjustments have also affected pricing strategies and contract negotiations across distribution channels, prompting suppliers to explore longer-term agreements with health systems and group purchasing organizations to stabilize demand and cash flow. In parallel, regulatory and customs compliance functions have assumed greater prominence within commercial operations, with firms investing in trade advisory capabilities and automated classification processes to optimize tariff outcomes. The cumulative effect of these adaptations has been a reframing of risk management practices across manufacturing, distribution, and commercial functions, reinforcing the importance of agile supply chain architectures and close coordination between procurement, regulatory, and commercial teams.

Strategic segmentation interplay across product types, end users, applications, technologies, distribution channels, and sample types to guide product and commercial prioritization

A granular understanding of segmentation is essential to align product design, evidence generation, and go-to-market approaches. When considering product type, the market spans coagulation, endocrinology, hematology, immunochemistry, lateral flow immunoassays, molecular diagnostics, and urinalysis, with coagulation platforms further split into PT INR meters and thromboelastography devices, endocrinology solutions including glucose meters and insulin pumps, hematology covering hemoglobin meters and white blood cell counters, immunochemistry comprising chemiluminescence immunoassay, enzyme linked immunosorbent assay, and fluorescence immunoassay, lateral flow tests including antibody tests, antigen tests, and multiplex tests, molecular diagnostics encompassing isothermal amplification, next generation sequencing, and PCR, and urinalysis delivered through analyzer systems and test strips. Understanding these product distinctions clarifies the performance, regulatory, and usability expectations across settings.

End user segmentation-spanning clinics, home care, hospitals, mobile testing, and physician offices-directly influences requirements for workflow integration, connectivity, and training. Applications such as cardiology, diabetes monitoring, infectious diseases, oncology, and pregnancy testing each impose unique analytical demands and evidence needs that shape clinical acceptance. Technology choices including electrochemical detection, immunoassay, microfluidic platforms, molecular diagnostics, and optical detection influence cost structures and scalability, with immunoassay technologies frequently represented by chemiluminescence, ELISA, fluorescence methods, and lateral flow formats, and molecular diagnostics often leveraging isothermal amplification, next generation sequencing, and PCR. Distribution channels, whether direct tender, distributor sales, e-commerce, or retail pharmacies, determine sales cycles and margin profiles. Finally, sample type considerations-blood, breath, saliva, and urine-affect collection workflows and user comfort, which in turn influence adoption in decentralized settings. Integrating these segmentation dimensions enables clearer prioritization of clinical validation, user experience design, and channel strategies.

Regional regulatory variability, procurement dynamics, and digital infrastructure differences driving differentiated strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics vary significantly and must inform go-to-market and regulatory planning. The Americas continue to emphasize integrated care networks, value-based reimbursement pilot programs, and consolidation among healthcare providers, which shapes demand for devices that deliver measurable outcomes and operational efficiencies. Meanwhile, Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where national-level health technology assessment processes and procurement practices require tailored market access strategies; in several countries, public tenders and hospital group negotiations remain pivotal for adoption. In the Asia-Pacific region, diverse market maturities coexist, with some markets rapidly adopting point-of-care molecular testing and home monitoring solutions, and others prioritizing scalable, low-cost lateral flow and electrochemical platforms to expand testing access.

These regional distinctions extend to supply chain considerations, where logistics, customs treatment, and regional manufacturing capacity influence where companies choose to localize production or hold safety stocks. Additionally, digital health infrastructure and interoperability standards differ across regions, affecting the ease with which connected diagnostic solutions can be integrated into electronic health records and national health information exchanges. A regionally nuanced approach that aligns evidence generation, pricing, and distribution with local regulatory and reimbursement realities will be essential for sustained adoption and commercial success.

Competitive dynamics combining incumbent scale, startup agility, and strategic partnerships to differentiate on evidence, connectivity, and user experience in point-of-care diagnostics

Competitive dynamics in point-of-care diagnostics are shaped by a mix of established diagnostic manufacturers, fast-moving clinical startups, and specialized platform providers. Incumbent firms leverage broad product portfolios, established distribution networks, and existing hospital relationships to defend market positions, while nimble entrants focus on user-centric design, rapid iteration, and targeted evidence programs to penetrate specific applications or end-user segments. Partnerships between diagnostic developers and digital health vendors are accelerating, as connectivity and data analytics capabilities become differentiating features that unlock value across care pathways.

In addition, strategic collaborations with contract manufacturers and component suppliers are increasingly common as firms seek to optimize production flexibility and reduce time-to-market for upgrades and new assays. Mergers and acquisitions remain an important route for expanding assay menus and enhancing technological capabilities, while licensing agreements enable quicker access to complementary technologies. Competitive advantage is therefore multifaceted: analytical performance remains necessary but not sufficient; companies that combine strong clinical validation, streamlined user experience, integrated data workflows, and flexible commercial models are best positioned to win adoption across clinical and non-traditional care settings.

Practical and high-impact actions for leaders to secure clinical adoption, supply resilience, and commercial scalability through evidence-driven product and channel strategies

Industry leaders should adopt a proactive, multi-dimensional strategy that aligns product development, evidence generation, and commercial execution. Prioritize designing solutions with end users in mind by conducting iterative usability studies in clinics, hospitals, physician offices, mobile testing units, and home care environments to reduce training burden and optimize workflow integration. Concurrently, invest in pragmatic clinical trials and real-world evidence programs focused on application areas such as cardiology, diabetes monitoring, infectious diseases, oncology, and pregnancy testing to demonstrate clinical utility and economic value in contexts that matter to payers and providers.

From an operational perspective, diversify supply chains and consider regional manufacturing or strategic inventory placement to reduce exposure to trade policy shocks. Embrace modular and platform-based product architectures that allow rapid assay updates and multi-analyte expansion without full system redesign. Commercially, tailor distribution strategies to the target end user and channel dynamics-direct tender and distributor sales for institutional clients, e-commerce and retail pharmacy strategies for consumer-facing products, and hybrid models where warranted. Finally, embed interoperability and secure data sharing into product roadmaps to support integration with electronic health records and population health tools, thereby enhancing stickiness and enabling additional value-added services.

Robust multi-source research approach combining primary stakeholder interviews, technical benchmarking, literature synthesis, and trade and policy analysis to ensure actionable insights

The research methodology underpinning this analysis combined a multi-source approach designed to provide a balanced and actionable perspective. Primary research included structured interviews with clinicians, procurement professionals, and industry executives to capture frontline usability insights and procurement priorities across hospitals, clinics, mobile testing services, physician offices, and home care programs. Secondary research involved evaluation of peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to validate technological trends and clinical evidence trajectories.

Analysts synthesized qualitative inputs with technical benchmarking of assay platforms and device ergonomics, assessing how technologies such as electrochemical detection, immunoassay formats, molecular diagnostics, microfluidic implementations, and optical detection perform against real-world use cases. Trade and policy analysis examined the implications of tariff changes and procurement regulations on supply chain configurations and commercial contracts. Throughout, findings were triangulated across sources to prioritize robustness and relevance for decision-makers focused on product development, market access, and commercial operations.

Synthesis of strategic imperatives for product developers and healthcare leaders aiming to embed rapid diagnostics into care pathways and commercial ecosystems

In conclusion, point-of-care and rapid diagnostics are at a strategic inflection point where technological capability, care delivery transformation, and commercial innovation intersect to redefine where and how diagnostic decisions are made. Success in this environment will require more than strong analytical performance; it demands integrated strategies that address clinical utility, user experience, supply chain resilience, and evidence that resonates with payers and providers. Stakeholders who align product development with real-world use cases, proactively manage geopolitical and tariff-related risks, and deploy flexible distribution and commercialization models will be best positioned to capture the emerging opportunities.

Looking ahead, the emphasis will be on solutions that fit seamlessly into care pathways, provide interoperable data for clinical and population health use, and demonstrate measurable impact on outcomes and costs. For organizations willing to invest in pragmatic evidence generation, agile manufacturing partnerships, and user-centric design, the evolving landscape presents substantial opportunities to influence patient care at the point of decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point-Of-Care Or Rapid Diagnostics Market, by Product Type

  • 8.1. Coagulation
    • 8.1.1. PT INR Meters
    • 8.1.2. Thromboelastography Devices
  • 8.2. Endocrinology
    • 8.2.1. Glucose Meters
    • 8.2.2. Insulin Pumps
  • 8.3. Hematology
    • 8.3.1. Hemoglobin Meters
    • 8.3.2. White Blood Cell Counters
  • 8.4. Immunochemistry
    • 8.4.1. Chemiluminescence Immunoassay
    • 8.4.2. Enzyme Linked Immunosorbent Assay
    • 8.4.3. Fluorescence Immunoassay
  • 8.5. Lateral Flow Immunoassays
    • 8.5.1. Antibody Tests
    • 8.5.2. Antigen Tests
    • 8.5.3. Multiplex Tests
  • 8.6. Molecular Diagnostics
    • 8.6.1. Isothermal Amplification
    • 8.6.2. Next Gen Sequencing
    • 8.6.3. PCR
  • 8.7. Urinalysis
    • 8.7.1. Analyzer Systems
    • 8.7.2. Test Strips

9. Point-Of-Care Or Rapid Diagnostics Market, by Technology

  • 9.1. Electrochemical Detection
  • 9.2. Immunoassay
    • 9.2.1. Chemiluminescence Immunoassay
    • 9.2.2. ELISA
    • 9.2.3. Fluorescence Immunoassay
    • 9.2.4. Lateral Flow Immunoassay
  • 9.3. Microfluidic Platforms
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal Amplification
    • 9.4.2. Next Gen Sequencing
    • 9.4.3. PCR
  • 9.5. Optical Detection

10. Point-Of-Care Or Rapid Diagnostics Market, by Sample Type

  • 10.1. Blood
  • 10.2. Breath
  • 10.3. Saliva
  • 10.4. Urine

11. Point-Of-Care Or Rapid Diagnostics Market, by Application

  • 11.1. Cardiology
  • 11.2. Diabetes Monitoring
  • 11.3. Infectious Diseases
  • 11.4. Oncology
  • 11.5. Pregnancy Testing

12. Point-Of-Care Or Rapid Diagnostics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Mobile Testing
  • 12.5. Physician Offices

13. Point-Of-Care Or Rapid Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Point-Of-Care Or Rapid Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Point-Of-Care Or Rapid Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Point-Of-Care Or Rapid Diagnostics Market

17. China Point-Of-Care Or Rapid Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Acon Laboratories, Inc.
  • 18.7. Becton Dickinson and Company
  • 18.8. Chembio Diagnostic Systems, Inc.
  • 18.9. Danaher Corporation
  • 18.10. EKF Diagnostics Holdings plc
  • 18.11. Hologic, Inc.
  • 18.12. Jianchun Biological Technology Co., Ltd.
  • 18.13. Meridian Bioscience, Inc.
  • 18.14. Nova Biomedical Corporation
  • 18.15. OraSure Technologies, Inc.
  • 18.16. Polymer Technology Systems, Inc.
  • 18.17. QIAGEN N.V.
  • 18.18. QuidelOrtho Corporation
  • 18.19. Response Biomedical Corp.
  • 18.20. Samsung Electronics Co., Ltd.
  • 18.21. Sekisui Diagnostics, LLC
  • 18.22. Siemens Healthineers AG
  • 18.23. Sysmex Corporation
  • 18.24. Trinity Biotech plc
  • 18.25. Veredus Laboratories Pte Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PT INR METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PT INR METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PT INR METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY THROMBOELASTOGRAPHY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY THROMBOELASTOGRAPHY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY THROMBOELASTOGRAPHY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMOGLOBIN METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMOGLOBIN METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMOGLOBIN METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY WHITE BLOOD CELL COUNTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY WHITE BLOOD CELL COUNTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY WHITE BLOOD CELL COUNTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MULTIPLEX TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MULTIPLEX TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MULTIPLEX TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANALYZER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANALYZER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANALYZER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY OPTICAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY OPTICAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY OPTICAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BREATH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BREATH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BREATH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOBILE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOBILE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOBILE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS,